Zebrafish modeling of intestinal injury, bacterial exposures, and medications defines epithelial in vivo responses relevant to human inflammatory bowel disease

Author:

Chuang Ling-shiang12ORCID,Morrison Joshua13,Hsu Nai-yun12ORCID,Labrias Philippe Ronel1ORCID,Nayar Shikha1ORCID,Chen Ernie12ORCID,Villaverde Nicole1ORCID,Facey Jody Ann1,Boschetti Gilles4ORCID,Giri Mamta1ORCID,Castillo-Martin Mireia5,Thin Tin Htwe5ORCID,Sharma Yashoda1,Chu Jaime3ORCID,Cho Judy H.12ORCID

Affiliation:

1. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA

2. The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, USA

3. Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, USA

4. Department of Oncological Science, Icahn School of Medicine at Mount Sinai, New York, USA

5. Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, USA

Abstract

Genome-wide association studies have identified over 200 genomic loci associated to inflammatory bowel disease (IBD)1. High effect risk alleles define key roles for genes involved in bacterial response and innate defense2. More high-throughput in vivo systems are required to rapidly evaluate therapeutic agents. We visualize, in zebrafish, the effects on epithelial barrier function and intestinal autophagy of one-course and repetitive injury. Repetitive injury induces increased mortality, impaired recovery of intestinal barrier function, failure to contain bacteria within the intestine, and impaired autophagy. PGE2 administration protected against injury by enhancing epithelial barrier function and limiting systemic infection. Effects of IBD therapeutic agents were defined; mesalamine showed protective features during injury while 6-mercaptopurine displayed marked induction of autophagy during recovery. Given the highly conserved nature of innate defense in zebrafish, it represents an ideal model system with which to test established and new IBD therapies targeted to the epithelial barrier.

Funder

National Institutes of Health

Crohn's and Colitis Foundation

Gilead Sciences

Publisher

The Company of Biologists

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology and Microbiology (miscellaneous),Medicine (miscellaneous),Neuroscience (miscellaneous)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3